Smith & Nephew PLC (SNN)
23.84
-0.16
(-0.69%)
USD |
NYSE |
Apr 19, 16:00
23.84
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 10.42B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -16.57% |
| Valuation | |
| PE Ratio | 39.61 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 1.877 |
| Price to Book Value | 1.998 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.462 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.553 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 55.07% |
Profile
| Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 41% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder. |
| URL | https://www.smith-nephew.com |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | Aug. 01, 2024 (est.) |
| Last Earnings Release | Feb. 27, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Apr. 01, 2024 |
Ratings
Profile
| Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 41% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder. |
| URL | https://www.smith-nephew.com |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | Aug. 01, 2024 (est.) |
| Last Earnings Release | Feb. 27, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Apr. 01, 2024 |